GMP Process for High-Quality iPSC Manufacturing and Development of Improved Differentiation Methodologies
Summary: Numerous protocols have been reported for generating differentiated derivatives of iPS cells. However, for these protocols to be clinically applicable, procedures must be simplified, display a high degree of robustness, be cost-effective, scalable, and compatible with GMPs. Furthermore, meaningful assays need to be developed to assesses impurities in the product and monitor its potency.
In this webinar, experts will discuss the evolution of protocols associated with induced pluripotent stem cell (iPSC) generation and differentiation. Hence, beyond the iPSC manufacturing workflow, the presentation will also highlight the development of advanced GMP-compatible protocols for converting these cells into several cell types of medical relevance, including retinal pigment epithelium (RPE), mesenchymal stem cells (MSCs), cardiomyocytes, and immune (NK) cells. Data will illustrate these new procedures to produce differentiated cells from iPSCs at high efficiency in a GMP-compatible manner without the need for complex cell handling procedures based on rational signaling pathway perturbations.